GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Opiant Pharmaceuticals Inc (NAS:OPNT) » Definitions » EV-to-EBITDA

Opiant Pharmaceuticals (Opiant Pharmaceuticals) EV-to-EBITDA : -2.93 (As of May. 12, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Opiant Pharmaceuticals EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Opiant Pharmaceuticals's enterprise value is $89.94 Mil. Opiant Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 was $-30.70 Mil. Therefore, Opiant Pharmaceuticals's EV-to-EBITDA for today is -2.93.

The historical rank and industry rank for Opiant Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:

OPNT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.51   Med: -1.21   Max: 280.61
Current: -2.93

During the past 13 years, the highest EV-to-EBITDA of Opiant Pharmaceuticals was 280.61. The lowest was -26.51. And the median was -1.21.

OPNT's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 9.49 vs OPNT: -2.93

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-12), Opiant Pharmaceuticals's stock price is $20.65. Opiant Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was $-6.570. Therefore, Opiant Pharmaceuticals's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Opiant Pharmaceuticals EV-to-EBITDA Historical Data

The historical data trend for Opiant Pharmaceuticals's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals EV-to-EBITDA Chart

Opiant Pharmaceuticals Annual Data
Trend Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20 Dec21
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.74 -1.46 2.58 -3.18 22.21

Opiant Pharmaceuticals Quarterly Data
Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.58 22.21 -19.82 -2.07 -1.19

Competitive Comparison of Opiant Pharmaceuticals's EV-to-EBITDA

For the Biotechnology subindustry, Opiant Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Opiant Pharmaceuticals's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's EV-to-EBITDA falls into.



Opiant Pharmaceuticals EV-to-EBITDA Calculation

Opiant Pharmaceuticals's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=89.936/-30.697
=-2.93

Opiant Pharmaceuticals's current Enterprise Value is $89.94 Mil.
Opiant Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-30.70 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Opiant Pharmaceuticals  (NAS:OPNT) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Opiant Pharmaceuticals's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=20.65/-6.570
=At Loss

Opiant Pharmaceuticals's share price for today is $20.65.
Opiant Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.570.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Opiant Pharmaceuticals EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals (Opiant Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
233 Wilshire Boulevard, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
David D O'toole officer: Chief Financial Officer 1640 MARENGO STREET, LOS ANGELES CA 90033
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC., 201 SANTA MONICA BLVD., SUITE 500, SANTA MONICA CA 90401
Roger Crystal director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE, 10TH FL., NEW YORK NY 10022
Phil Skolnick officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC., 433 HACKENSACK AVENUE, HACKENSACK NJ 07601
Brian Gorman other: General Counsel 233 WILSHIRE BLVD, SUITE 280, SANTA MONICA CA 90401
Matthew R. Ruth officer: Chief Commercial Officer 233 WILSHIRE BLVD., SUITE 280, SANTA MONICA CA 90401
Michael Sinclair director, 10 percent owner, officer: Executive Chairman 86 GLOUCESTER PLACE, LONDON XX W1U6HP
Craig A Collard director C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Ann L. Macdougall director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Thomas T. Thomas director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Masuoka K. Lorianne director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Gabrielle Alison Silver director C/O OPIANT PHARMACEUTICALS, INC., 401 WILSHIRE BOULEVARD, 12TH FLOOR, SANTA MONICA CA 90401
Rahsaan Thompson other: General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Aziz Mottiwala officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Richard J Daly director 355 ALHAMBRA CIRCLE, SUITE 1500, CORAL GABLES FL 33134

Opiant Pharmaceuticals (Opiant Pharmaceuticals) Headlines

From GuruFocus

Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

By Stock market mentor Stock market mentor 02-07-2023

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, CBIO

By Stock market mentor Stock market mentor 01-08-2023